Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06705764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)

Study acronym: TERAA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Recruitment opened
    • Site details revised at 2 of 2 sites
    v9
  2. Notable Start date: Apr 1, 2026 to May 11, 2026v8
  3. Notable Start date: Feb 2, 2026 to Apr 1, 2026v7
  4. Notable Start date: Nov 24, 2025 to Feb 2, 2026v6
  5. Notable Primary completion date: Nov 2025 to Nov 2026
    • Start date: Sep 1, 2025 to Nov 24, 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: Apr 15, 2025 to Sep 1, 2025v4
  2. Notable Start date: Jan 30, 2025 to Apr 15, 2025v3
  3. Notable Start date: Nov 30, 2024 to Jan 30, 2025v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
956 trials monitored
See 34 trials at risk
Adults with severe asthma may have sudden worsening shortness of breath that results in their going to Emergency Department for urgent care. Emergency Room visits for asthma management across Alberta have been reviewed and it has been found that adults frequently need to return for repeated worsening. This is a large drain on health care resources as well as being very distressing for individuals with asthma. Occasionally this results in admission to hospital and rarely may lead to death. People are often treated with steroids to try to prevent the need for Emergency Room visits even though steroid medications have many long term bad side effects. A new medication for patients considered to have severe asthma has been recently approved by Health Canada. This medication, Tezepelumab, is a monthly injection and it helps control asthma in adults regardless of the underlying cause. The study will examine if starting Tezepelumab, compared with a placebo, in the Emergency Room will help settle symptoms of asthma and prevent future worsening requiring repeated Emergency Room visits or the need for courses of outpatient steroid medications.
Trial Details
NCT Number NCT06705764
Lead Sponsor University of Alberta
Collaborators: AstraZeneca
Conditions
(from sponsor)
Severe Asthma
Related terms Asthma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov